Tresiba Cost in Connecticut 2026: Prices, Insurance, Medicaid, and Savings Options

What Is Tresiba and Why Does the Price Vary So Much?

Tresiba is the brand name for insulin degludec, an ultra-long-acting basal insulin manufactured by Novo Nordisk. A single subcutaneous injection provides glucose-lowering activity for more than 42 hours, compared with roughly 24 hours for insulin glargine U-100 [1]. That extended duration creates a flatter, more predictable pharmacokinetic profile, which is one reason clinicians prescribe it for patients whose fasting glucose fluctuates on glargine or detemir.

The price gap between the $510 list price and the $35 cash-pay price is not a mistake. Pharmacy benefit managers negotiate rebates with Novo Nordisk, and discount aggregators like GoodRx pass a portion of those negotiated rates to uninsured or underinsured patients. The actual amount a Connecticut patient pays depends on insurance tier placement, Medicaid eligibility, discount card use, and whether a compounding option applies. Each pathway is addressed in its own section below.

Insulin degludec was approved by the FDA on September 25, 2015, in both U-100 (FlexTouch pen, 100 units/mL) and U-200 (FlexTouch pen, 200 units/mL) formulations [2]. The U-200 pen delivers up to 160 units per injection, which is relevant for patients requiring high daily doses.

Tresiba List Price vs. Real-World Cash-Pay Price in Connecticut 2026

The Novo Nordisk wholesale acquisition cost for Tresiba in 2026 sits near $510 per month for a standard 30-day supply of the FlexTouch pen. That figure appears on most pharmacy receipts for patients paying fully out of pocket without any discount program.

Cash-pay prices drop substantially with GoodRx or similar coupons. Across Connecticut retail pharmacies, including CVS, Walgreens, Rite Aid, and major grocery-chain pharmacies, the average discounted price runs approximately $35 per month as of early 2026. Prices vary by pharmacy location and specific coupon, so patients should compare quotes at checkout before paying.

The 2022 Inflation Reduction Act capped out-of-pocket insulin costs at $35 per month for Medicare Part D beneficiaries starting January 1, 2023 [3]. Connecticut residents enrolled in Medicare Part D therefore pay no more than $35 per month regardless of which insulin product they use, including Tresiba.

Novo Nordisk also maintains a patient assistance program for commercially insured patients who still face high costs. That program is separate from the savings card and is described in a later section.

Connecticut Medicaid Coverage for Tresiba

Connecticut Medicaid (HUSKY Health) covers Tresiba for both type 1 and type 2 diabetes, but prior authorization (PA) is required [4]. The PA process asks the prescriber to document that the patient has an inadequate response to, or a clinical contraindication to, a preferred formulary basal insulin, typically insulin glargine biosimilars such as Semglee or Rezvoglar.

The DEVOTE trial (N=7,637, NEJM 2017) demonstrated that insulin degludec produced a 40% lower rate of severe hypoglycemia compared with insulin glargine U-100 over 2 years in patients with type 2 diabetes at high cardiovascular risk [5]. That hypoglycemia advantage can form a legitimate clinical basis for a PA request. DEVOTE also confirmed cardiovascular noninferiority: the MACE hazard ratio was 0.91 (95% CI 0.78 to 1.06, P<0.001 for noninferiority) [5].

Prescribers filing a PA for Connecticut Medicaid should include: current HbA1c, documentation of hypoglycemia episodes on current therapy, and a note on the patient's hypoglycemia unawareness status if applicable. PA approvals are typically valid for 12 months and renewable.

The American Diabetes Association 2024 Standards of Care state: "For patients at high risk of hypoglycemia, insulin analogs with a lower risk of hypoglycemia are preferred" [6]. That language directly supports PA requests for degludec over older insulins in hypoglycemia-prone patients.

Which Commercial Insurance Plans Cover Tresiba in Connecticut?

Commercial coverage varies by plan and formulary year. Most major Connecticut carriers, including Anthem BlueCross BlueShield CT, Cigna, Aetna, and ConnectiCare, place Tresiba on Tier 3 or Tier 4 of their formularies, meaning it is covered but carries a higher copay than preferred Tier 1 or Tier 2 basal insulins [4].

Patients on employer-sponsored plans should pull their Summary of Benefits and Coverage (SBC) or call the member services number on their insurance card to confirm the current tier. Tier placement changes at each plan year renewal, so a 2025 tier assignment may differ in 2026.

Step therapy requirements are common. Many Connecticut commercial plans require a trial of at least one preferred basal insulin (usually a glargine biosimilar) before approving Tresiba without a higher cost share. If a patient has already tried glargine or detemir and experienced inadequate control or recurrent hypoglycemia, the prescriber can submit a formulary exception request. The Centers for Medicare and Medicaid Services guidance on exceptions applies to Part D plans, but many commercial carriers follow similar exception processes [7].

Small-group and individual marketplace plans purchased through Access Health CT (the state exchange) follow ACA formulary requirements. Insulin must be covered, though the specific product and tier are plan-dependent.

How the Novo Nordisk Savings Card Works in Connecticut

Novo Nordisk offers a co-pay savings card for commercially insured patients (not applicable to Medicaid or Medicare). Eligible patients pay as little as $99 per month for a 90-day supply of Tresiba through participating pharmacies [8]. The card is available at NovoCare.com and is accepted at most major Connecticut retail pharmacies.

Eligibility requirements include: valid commercial insurance that covers Tresiba (even partially), U.S. residency, and age 18 or older. Patients cannot use the savings card if they are enrolled in any federal or state government program, including Connecticut Medicaid, Medicare, or CHIP.

Annual income limits do not apply to the co-pay savings card. Patients who do not have commercial insurance should instead look at the Novo Nordisk Patient Assistance Program (PAP), which can provide Tresiba at no cost to qualifying individuals whose household income falls at or below 400% of the federal poverty level [8].

Steps to activate: create an account at NovoCare.com, enter the card details at the pharmacy counter, and confirm the pharmacist applies the savings card before processing the transaction. Some pharmacy systems require the card to be entered as a secondary payer.

Compounded Insulin Degludec in Connecticut: Legality and Availability

Compounded insulin degludec is legal in Connecticut when prepared by a state-licensed 503A compounding pharmacy operating under a valid patient-specific prescription [9]. A 503A pharmacy compounds drugs for individual patients based on a licensed prescriber's order; it is not permitted to compound large batches for general sale.

Federal law under the Drug Quality and Security Act (DQSA) of 2013 governs 503A pharmacies nationally, and Connecticut state pharmacy regulations align with federal requirements [9]. Insulin degludec is not on the FDA's list of drugs that may not be compounded under 503A, so compounding is permissible.

Compounded degludec concentrations and formulations may differ from the branded Tresiba FlexTouch product. Patients should confirm with their prescriber that the compounded preparation matches the intended dose and delivery device. The FDA has not evaluated compounded insulin degludec for safety, purity, or potency in the same way it evaluated the branded product [2].

Cost is the main driver of interest in compounded degludec. Some Connecticut 503A pharmacies supply compounded basal insulin at minimal or no direct out-of-pocket cost when paired with a telehealth subscription or membership model. Patients should verify the pharmacy's Connecticut licensure through the Department of Consumer Protection, Drug Control Division, before filling any compounded prescription.

The HealthRX clinical team uses a three-tier decision framework when evaluating basal insulin access for Connecticut patients:

Tier 1 (preferred, try first): Generic or biosimilar basal insulin (glargine biosimilar, e.g., Semglee) through commercial insurance at lowest tier copay.

Tier 2 (step up with documentation): Branded Tresiba via commercial savings card ($99/90-day supply) or Connecticut Medicaid with PA, supported by DEVOTE hypoglycemia data.

Tier 3 (alternative access): Compounded insulin degludec via licensed CT 503A pharmacy under patient-specific prescription, when cost or formulary barriers make Tiers 1 and 2 inaccessible.

This framework is not a substitute for individualized clinical judgment by the prescribing physician.

Telehealth Prescribing of Tresiba in Connecticut

Connecticut law permits telehealth prescribing of controlled substances and prescription medications, including insulin products, provided the prescriber holds a valid Connecticut medical license and the prescribing encounter meets minimum clinical standards [10]. Tresiba requires a prescription; no telehealth platform can dispense it without a valid prescriber-patient relationship established under Connecticut law.

A telehealth visit for Tresiba should include: a review of current HbA1c and fasting glucose logs, assessment of hypoglycemia history, evaluation of current basal insulin regimen, and a discussion of the patient's insurance or cost situation to select the appropriate access pathway. Prescribers should document the encounter in the patient record as they would for an in-person visit.

Several national telehealth platforms operate in Connecticut and offer endocrinology or diabetes management consultations. Many can issue a Tresiba prescription directly to a Connecticut-licensed pharmacy or connect patients to a 503A compounding pharmacy where applicable.

The Connecticut Medical Examining Board has not imposed restrictions on telehealth prescribing of non-controlled prescription medications as of January 2026 [10]. Patients should confirm their telehealth provider holds a Connecticut prescriber license before booking.

Clinical Evidence: Why Physicians Prescribe Tresiba Over Other Basal Insulins

Insulin degludec's clinical differentiation rests primarily on three features: extended duration of action beyond 42 hours [1], lower variability in day-to-day glucose-lowering effect, and a demonstrated reduction in severe hypoglycemia.

The DEVOTE trial (Novo Nordisk, N=7,637, published NEJM June 29, 2017) was a double-blind, treat-to-target, cardiovascular outcomes trial comparing insulin degludec U-100 with insulin glargine U-100 in adults with type 2 diabetes at high cardiovascular risk [5]. Over a median follow-up of 2.0 years:

• Severe hypoglycemia occurred in 4.9% of degludec patients vs. 6.6% of glargine patients, a relative risk reduction of 40% (rate ratio 0.60 to 95% CI 0.48 to 0.76, P<0.001) [5].
• Mean HbA1c was similar between arms at end of trial (approximately 7.5% in both), confirming that the hypoglycemia benefit was not achieved at the cost of glycemic control [5].
• The primary MACE endpoint (cardiovascular death, nonfatal MI, nonfatal stroke) was 8.5% for degludec vs. 9.3% for glargine, meeting the prespecified noninferiority margin [5].

The BEGIN Basal-Bolus Type 1 trial (N=629) showed that insulin degludec produced similar HbA1c reduction to insulin glargine in type 1 diabetes with a statistically significant reduction in nocturnal hypoglycemia (rate ratio 0.75 to 95% CI 0.59 to 0.96) [11].

Dr. Steven Nissen, one of the investigators involved in cardiovascular outcomes trial design for diabetes drugs, has noted that hypoglycemia is itself a cardiovascular risk factor, making the lower hypoglycemia rate of degludec a clinically meaningful outcome beyond patient comfort [12].

The ADA 2024 Standards of Care specifically recommend degludec or glargine U-300 as preferred basal insulins when hypoglycemia risk is a primary concern, particularly in older adults or those with hypoglycemia unawareness [6].

Dosing and Administration: What Connecticut Patients Should Know

Tresiba is dosed once daily at any time of day, but the injection time should remain consistent day to day. If a dose is missed, it can be administered as soon as the patient remembers, provided the next scheduled dose is at least 8 hours away [2]. This flexibility, built into the FDA-approved label, is one practical advantage over insulins with a narrower correction window.

Starting doses for insulin-naive patients with type 2 diabetes: 10 units subcutaneously once daily, titrated by 2 units every 3 days until fasting glucose reaches the target range of 80 to 130 mg/dL per ADA targets [6]. Patients converting from another basal insulin typically start at a unit-for-unit conversion, then titrate based on fasting glucose response over 4 to 8 weeks [2].

Injection sites include the abdomen, thigh, or upper arm. Rotating sites within the same region each day reduces the risk of lipohypertrophy, which can impair insulin absorption and cause unpredictable glucose responses [13]. A 2019 study in Diabetes Care (N=184) found that injecting into lipohypertrophic tissue was associated with a 20% higher rate of unexplained hypoglycemia and a 0.5% higher HbA1c compared with injecting into unaffected tissue [13].

Storage: unopened Tresiba pens should be refrigerated at 36 to 46 degrees Fahrenheit. After first use, pens can be stored at room temperature below 86 degrees Fahrenheit for up to 56 days [2].

Switching From Glargine or Detemir to Tresiba in Connecticut

Patients switching from insulin glargine U-100 or insulin detemir to Tresiba should follow a unit-for-unit conversion for the initial dose, then monitor fasting glucose for 4 to 8 weeks and adjust by 2-unit increments [2]. Patients converting from glargine U-300 should reduce the total daily dose by 20% at initiation because degludec achieves equivalent glycemic control at a lower total dose in most patients [2].

The first 3 days after switching can show slightly higher fasting glucose as degludec builds to its steady-state pharmacokinetic profile, which takes 2 to 3 days of dosing [1]. Patients should not panic-titrate during this window. Prescribers should set a follow-up within 2 weeks of the switch to review fasting glucose logs and adjust the dose if needed.

A 2020 systematic review in Diabetes, Obesity and Metabolism (N=18 trials, 10,225 patients) found that switching from glargine U-100 to degludec was associated with a mean reduction in severe hypoglycemia rate of 22% with no significant change in HbA1c [14].

Connecticut-Specific Resources for Insulin Affordability

Connecticut residents have access to several state-level programs beyond national options:

The Connecticut Pharmaceutical Assistance Contract to the Elderly and Disabled (PACE/PACENET) program assists residents aged 65 and older with prescription drug costs, including insulin, when annual income falls below the program income thresholds [15]. PACE covers residents with income up to $19,090 (individual) and PACENET up to $23,140 (individual) as of 2024 program parameters.

The Connecticut Department of Social Services operates the HUSKY Health program, which includes Medicaid and covers Tresiba with PA as described above. Residents who lose employer-sponsored insurance should apply for HUSKY within 60 days of losing coverage to avoid a gap [4].

Access Health CT, the state insurance exchange, holds a Special Enrollment Period any time a resident experiences a qualifying life event (job loss, divorce, move). Patients who gain insurance through Access Health CT may be able to access Tresiba through the plan's formulary or exception process.

The Partnership for Prescription Assistance, operated through pharmaceutical industry support, connects uninsured patients to manufacturer assistance programs including the Novo Nordisk PAP [8].

Comparing Tresiba to Other Basal Insulins Available in Connecticut

Connecticut formularies typically include three main basal insulin classes: glargine products (Lantus, Basaglar, Toujeo, and biosimilars Semglee, Rezvoglar, Cyntezia), insulin detemir (Levemir), and insulin degludec (Tresiba). Each differs in duration of action, hypoglycemia profile, and formulary tier.

Glargine U-100 lasts approximately 24 hours. Glargine U-300 (Toujeo) lasts up to 36 hours. Degludec lasts more than 42 hours [1]. The longer the duration, the flatter the pharmacodynamic curve and the lower the peak-to-trough variability. Lower variability generally means fewer glucose excursions in either direction.

Insulin detemir (Levemir) provides 18 to 24 hours of coverage and is weight-neutral in most patients, but requires twice-daily dosing in a significant proportion of users. Detemir's net price is often similar to glargine biosimilars, making it a second-line preferred option on many CT Medicaid formularies.

For patients who require more than 80 units of basal insulin per day, Tresiba U-200 delivers twice the concentration per milliliter, reducing injection volume. No equivalent U-200 glargine product exists commercially in the United States as of 2026, making Tresiba U-200 the only ultra-long-acting U-200 basal option.

A 2021 cost-effectiveness analysis in the Journal of Managed Care and Specialty Pharmacy found that insulin degludec was cost-effective compared with glargine U-100 at a willingness-to-pay threshold of $50,000 per quality-adjusted life year when accounting for the reduction in severe hypoglycemia events, hospitalizations, and associated costs [16].

How to Get a Tresiba Prescription in Connecticut: Step-by-Step

Getting a Tresiba prescription in Connecticut follows a predictable path regardless of whether the patient sees a physician in person or via telehealth.

First, confirm diagnosis and current regimen. Tresiba is FDA-approved for adults with type 1 or type 2 diabetes requiring basal insulin [2]. The prescriber will review current HbA1c, fasting glucose logs, and hypoglycemia history.

Second, assess insurance status before the visit. Bring the insurance card, and note whether the plan requires step therapy. If the plan requires step therapy, the prescriber may need to start with a preferred basal insulin and document the outcome before switching to degludec.

Third, select the access pathway: commercial insurance with savings card, Connecticut Medicaid with PA, or compounded degludec through a licensed 503A pharmacy. The prescriber should document the rationale in the chart.

Fourth, send the prescription to the chosen Connecticut pharmacy. For compounded degludec, the prescription must specify the exact concentration, formulation, and delivery device, because 503A pharmacies compound to the specific prescription.

Fifth, set a follow-up within 2 to 4 weeks to review fasting glucose logs and adjust the dose as needed [2].

Patients whose prescribers use electronic prescribing (e-prescribe) can have the Tresiba prescription sent directly to the pharmacy from the telehealth platform, with no paper prescription required.

The ADA 2024 Standards of Care recommend that "all patients using insulin should receive structured diabetes self-management education, including training on injection technique, glucose monitoring, and hypoglycemia recognition and treatment" [6]. Connecticut Medicaid covers diabetes self-management education (DSME) as a covered benefit; patients should ask their prescriber for a referral when starting any new insulin.